Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Assess the Efficacy and Safety of HH-120 Nasal Spray for the Treatment of Mild COVID-19

NCT05713318 is registered in ClinicalTrials.gov with Huahui Health as lead sponsor.

NCT NCT05713318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05713318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Assess the Efficacy and Safety of HH-120 Nasal Spray for the Treatment of Mild COVID-19
Lead sponsor
Huahui Health
Phase
Phase 2
Overall status
Completed
Start date
January 18, 2023
Completion date
June 19, 2023
Enrollment
200 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19